Conflicting Sequencing Results in Breast Cancer: Unraveling the TP53 Mutation Mystery
Journal of Clinical Laboratory Analysis · 17.11.2026
DOI: 10.1002/jcla.70374 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Laboratory Analysis, online erschienen am 17.11.2026. Verfasst von Jiajia Song und 3 weiteren Autor:innen. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
In early‐onset or familial breast cancer, NGS is routinely used for germline mutation screening. However, detection of pathogenic variants at low allele frequencies may complicate clinical diagnosis. Case Presentation We report a case of advanced breast cancer in which a TP53 mutation identified in whole blood likely reflects tumor‐derived circulating tumor DNA (ctDNA) rather than a true germline event. A 45‐year‐old Chinese female with invasive lobular carcinoma underwent germline mutation analysis using NGS on peripheral blood, targeting 23 cancer‐related genes including TP53. NGS identified a TP53 missense mutation (NM_000546.6:c.818G>A; p.R273H) at a variant allele frequency of 26.28%. Validation was attempted via sanger sequencing, and NGS was subsequently repeated on isolated peripheral blood leukocytes after plasma removal to ascertain the mutation's origin. Although the initial NGS assay detected the TP53 p.R273H mutation at 26.28%, sanger sequencing did not confirm its presence. Moreover, NGS performed on plasma‐depleted leukocytes yielded a negative result. This unexpected divergence strongly suggests that the detected variant originated from tumor‐derived cfDNA rather than representing a bona fide germline mutation.
Conclusions
This case demonstrates that high levels of tumor‐derived cfDNA in advanced breast cancer can confound germline mutation detection, leading to discordant sequencing results. Our findings highlight the importance of employing complementary validation strategies and cautious interpretation of molecular data to avoid diagnostic errors and unnecessary interventions. Our case highlights critical pre‐analytical and analytical considerations in molecular diagnostics, urging laboratory professionals to adopt rigorous validation protocols in patients with high tumor burden.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Song, J., Liu, T., Si, Y., & Chen, H. (2026). Conflicting Sequencing Results in Breast Cancer: Unraveling the TP53 Mutation Mystery. Journal of Clinical Laboratory Analysis. https://doi.org/10.1002/jcla.70374
Vancouver
Song J, Liu T, Si Y, Chen H. Conflicting Sequencing Results in Breast Cancer: Unraveling the TP53 Mutation Mystery. Journal of Clinical Laboratory Analysis. 2026. doi:10.1002/jcla.70374
BibTeX
@article{Song2026,
author = {Song, Jiajia and Liu, Tangyuheng and Si, Yanjun and Chen, Hao},
title = {Conflicting Sequencing Results in Breast Cancer: Unraveling the TP53 Mutation Mystery},
journal = {Journal of Clinical Laboratory Analysis},
year = {2026},
doi = {10.1002/jcla.70374}
}
EUVIMED